Improvement of Work Productivity and Quality of Life with Anti-Tumor Necrosis Factor Treatment Used in Crohn's Disease in Routine Clinical Practice in Turkey

Basit Öğe Kaydı
dc.authoridSezgin, Orhan/0000-0002-6704-4716
dc.authorwosidAtug, Ozlen/JWA-5722-2024
dc.authorwosidSezgin, Orhan/ABK-6123-2022
dc.contributor.authorToruner, Murat
dc.contributor.authorBasaranoglu, Metin
dc.contributor.authorAtug, Ozlen
dc.contributor.authorSenturk, Omer
dc.contributor.authorAkyuz, Filiz
dc.contributor.authorCekic, Cem
dc.contributor.authorHamzaoglu, Hulya Over
dc.date.accessioned2024-06-12T10:52:10Z
dc.date.available2024-06-12T10:52:10Z
dc.date.issued2022
dc.departmentTrakya Üniversitesien_US
dc.description.abstractBackground: Patients with Crohn's disease experience major deterioration in work productivity and quality of life. We aimed to provide the long-term effects of anti-tumor necrosis factor agents on work productivity and activity impairment and quality of life in patients with Crohn's disease using the Inflammatory Bowel Disease Questionnaire and the Short-Form Health Survey-36. Methods: Patients with Crohn's disease and initiated an anti-tumor necrosis factor treatment were included and followed up for 12 months in this observational study. Results: A total of 106 patients were included in this study, and 64.2% of the patients were males. Mean [+/- standard deviation] age was 36.8 [+/- 10.9] years. At baseline, mostly perianal fistulas [65.7%] were observed [n = 23]. Intestinal stenosis was detected in 34.9% of the patients [n = 37], and most of the stenosis was located in the ileum [70.6%] followed by the colon [20.6%]. Extraintestinal symptoms were observed in 24 patients [22.6%]. Most frequent extraintestinal symptom was arthritis with 71.4% [n = 15]. Mean time from first symptom to initiation of anti-tumor necrosis factor treatment was 6.3 [+/- 5.0] years. Improvements in work productivity and activity impairment scores throughout 12 months were -24.1% [P =.003] for work time missed, -18.0% [P =.006] for impairment at work, -8.5% [P =.160] for overall work impairment, and -17.0% [P <.001] for daily activity impairment. Similarly, significant improvements [P <.001] were detected in all components of the Inflammatory Bowel Disease Questionnaire when compared to baseline. Statistically significant improvements [P <.05] were detected for all components of Short-Form Health Survey-36 except for mental health [P =.095]. Conclusion: Our study indicates the significant improvement in work productivity and activity impairment and quality of life of patients with Crohn's disease who receive long-term anti-tumor necrosis factor treatment.en_US
dc.description.sponsorshipAbbVie; Takeda; Genfit; Pfizer; Roche; Janssen; Gilead; Celltrion; UCBen_US
dc.description.sponsorshipThe design, study conduct, and financial support for this study were provided by AbbVie. AbbVie participated in study design, research, analysis and data collection, interpretation of data, and review and approval of this manuscript. All authors received investigator fee payments from AbbVie for participating in this study. In addition, Dr. Murat Toruner has received no research grant, received consulting and/or speaker fee from AbbVie, Amgen, MSD, Takeda, Janssen. Dr. Metin Basaranoglu received research grant from Takeda and Genfit; received speaker and/or consulting fee from AbbVie, MSD, UCB, Bayer, and Santa Farma. Dr. Ozlen Atug received no research grant; received consulting and/or speaker fee from AbbVie, MSD, Takeda, and Eczacibasi. Dr. Filiz Akyuz received research grant from Pfizer and Genfit; consulting fee from Medtronic and speaker fee from AbbVie, Ferring, and Reckitt Benckiser. Dr. Cem Cekic received no research grant and received speaker and/or consultancy fee from AbbVie, Celltrion, and Ferring. Dr. Hulya Over Hamzaoglu received research grant from Roche and Janssen and speaker fee from AbbVie, MSD, Takeda, Ferring and consultancy fees from AbbVie, MSD, Takeda, and Ferring. Dr. Orhan Sezgin received research grant from AbbVie and Gilead and speaker and/or consultancy fees from AbbVie, Abdi Ibrahim, Bilim, Takeda, Ferring, UCB, and Drogsan. Dr. Hale Akpinar received research grant from AbbVie, Celltrion, and Janssen and speaker and/or consultancy fees from Abbvie, Ferring, MSD, Takeda, and UCB. Dr. Aykut Ferhat Celik received research grant from AbbVie, Pfizer, Janssen, UCB, and Takeda and speaker and/or consultancy fees from Abbvie, Ferring, Eczacibasi, Janssen, UCB, and Takeda. Dr. Ahmet Tezel received research grant from Lilly and Pfizer and speaker and/or consultancy fee from AbbVie, Ali Raif, Eczacibasi, Ferring, MSD, Takeda, and Pfizer. Dr. Fatih Tekin, Dr. Omer Senturk, Dr. Huseyin Savas Gokturk, and Dr. Taylan Kav have no additional disclosures to declare.en_US
dc.identifier.doi10.5152/tjg.2022.21868
dc.identifier.endpage413en_US
dc.identifier.issn2148-5607
dc.identifier.issue5en_US
dc.identifier.pmid35678798en_US
dc.identifier.scopus2-s2.0-85131771442en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage406en_US
dc.identifier.trdizinid532767en_US
dc.identifier.urihttps://doi.org/10.5152/tjg.2022.21868
dc.identifier.urihttps://search.trdizin.gov.tr/yayin/detay/532767
dc.identifier.urihttps://hdl.handle.net/20.500.14551/18600
dc.identifier.volume33en_US
dc.identifier.wosWOS:000865997300005en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakTR-Dizinen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherAvesen_US
dc.relation.ispartofTurkish Journal Of Gastroenterologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectAnti-TNFen_US
dc.subjectCrohn's Diseaseen_US
dc.subjectQuality Of Lifeen_US
dc.subjectWork Productivityen_US
dc.subjectActivity Impairment Questionnaireen_US
dc.subjectInflammatory-Bowel-Diseaseen_US
dc.subjectCertolizumab Pegolen_US
dc.subjectMaintenanceen_US
dc.subjectAdalimumaben_US
dc.subjectTrialen_US
dc.subjectInfliximaben_US
dc.subjectRemissionen_US
dc.subjectModerateen_US
dc.subjectOutcomesen_US
dc.titleImprovement of Work Productivity and Quality of Life with Anti-Tumor Necrosis Factor Treatment Used in Crohn's Disease in Routine Clinical Practice in Turkeyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu